68% of Diabetes Patients Skip Routine Check-ups — How Hospitals Can Reverse This Before It's Too Late

Indonesia's Diabetes Crisis Is Not Just a Medical Problem — It's an Operational One

Indonesia is fighting a diabetes epidemic that most hospitals are only partially equipped to address. According to the International Diabetes Federation (IDF), Indonesia ranks fifth globally for the highest number of adults living with diabetes — an estimated 19.5 million people as of 2021, with projections reaching 28.6 million by 2040.^[1] Yet behind that staggering number lies an equally troubling figure: 14.3 million of those cases remain undiagnosed.^[1]

For the patients who have been diagnosed, the challenge shifts to a different kind of failure — staying in the care system. Studies consistently show that a majority of diabetic patients in Indonesia do not return for routine check-ups after their initial diagnosis. Research published in peer-reviewed journals indicates that medication adherence is low in approximately 24% of diabetes patients nationally, with some regional Puskesmas reporting non-compliance rates as high as 94%.^[2]Another study found that 53% of diabetes' lifetime medical costs are consumed by treating complications — complications that are largely preventable with consistent monitoring.^[3]

This is where the crisis becomes an operational problem. Hospitals and clinics across Indonesia see diabetic patients for an initial diagnosis or acute episode, then watch them disappear. No follow-up call is made. No reminder is sent. No one asks whether the patient took their medication this week. The result: avoidable complications escalate into emergency admissions, driving up costs for both patients and the health system — while the hospital loses the very patient relationships that sustain chronic disease programs.

Why 68% of Diabetic Patients Never Return — Understanding the Dropout Chain

The statistic is alarming: research on chronic disease outpatient adherence in Indonesia and comparable low-to-middle-income countries reveals that more than two-thirds of diabetic patients either skip or indefinitely delay their routine follow-up appointments.^[4] Outpatient non-attendance rates for chronic disease patients in general range from 23% to 35% globally,^[5] with Indonesia trending toward the higher end given structural barriers including transportation access, long queues at Puskesmas and hospital outpatient units, limited health literacy, and the everyday pressures of economic survival.

The dropout chain typically unfolds like this. A patient receives their diabetes diagnosis and prescription. They fill the prescription once. Life intervenes — work, family, cost — and the second refill gets delayed. No one from the hospital reaches out. Two months pass. The patient's blood glucose is no longer monitored. Complications quietly accumulate: neuropathy (affecting 64% of Indonesian diabetes patients), retinopathy (42%), and microvascular damage (28%).^[3] Eventually, an acute episode brings them back — not to an outpatient clinic, but to the emergency room. The cost of that admission dwarfs what consistent outpatient follow-up would have cost.

For the hospital, this pattern represents both a clinical failure and a financial one. BPJS Kesehatan claims data consistently shows that complications from poorly managed diabetes — including diabetic foot, end-stage renal disease, and cardiovascular events — rank among the highest-cost inpatient claims. Preventing these complications through continuous outpatient engagement is not only better for patients; it is demonstrably better for the health system's finances.

“53% of diabetes' lifetime medical costs are attributable to treating complications — the vast majority of which are preventable through consistent monitoring and medication adherence.” — Scientific Reports, Nature, 2024^[3]

The Hospital's Double Burden: Clinical Risk and Revenue Loss

When a diabetic patient disappears from the care system, two things happen simultaneously: the patient's health deteriorates, and the hospital loses a long-term revenue relationship. For hospitals with chronic disease programs, each active diabetes patient in a structured follow-up program represents predictable, recurring revenue — consultation fees, lab work (HbA1c, lipid panels, kidney function), and eventual specialist referrals. When that patient stops returning, the revenue stream ends until the patient re-enters through a crisis.

Crisis re-entry is expensive for everyone. Emergency admissions for diabetic emergencies (ketoacidosis, hyperosmolar states, severe hypoglycemia) involve ICU care, extended hospitalization, and specialist involvement. Under the BPJS tariff structure, many of these episodes are reimbursed at rates that barely cover actual costs — creating direct financial pressure on hospital margins. The preventive path — keeping the patient engaged in outpatient follow-up — is almost always more profitable for the hospital than reactive crisis management.

This is the fundamental argument for investing in follow-up infrastructure. Not as a charity initiative, but as a financially rational decision that aligns clinical and business outcomes. The question is: what does that infrastructure look like, and who builds it?

Why Traditional Follow-Up Systems Are Structurally Insufficient

Most hospitals in Indonesia attempt some form of patient follow-up through administrative staff — nurses calling patients on a list, WhatsApp messages sent individually, or printed appointment slips handed out at discharge. All of these approaches share the same structural weakness: they are manual, inconsistent, and do not scale.

• Manual calling: A nurse responsible for 50 patients cannot reliably call all of them monthly. High-priority cases get attention; stable patients are deprioritized until they are no longer stable.
• No personalization: Generic reminder SMS messages (“Please return for your check-up”) carry no contextual weight and are routinely ignored.
• Office-hours limitation: Staff can only follow up during working hours. Patients who work daytime jobs — the majority of working-age diabetics — are unavailable exactly when staff are trying to reach them.
• No symptom monitoring: Traditional follow-up systems have no mechanism to detect when a patient is experiencing early warning signs between appointments. By the time the hospital learns of a problem, it is often a crisis.
• No feedback loop: There is no systematic way to know how many patients received, read, and acted on reminders — making improvement impossible.

The solution cannot be adding more human resources. It must be deploying intelligent automation that operates continuously, personalized to each patient's schedule and condition.

How Qlar's hc-followup Agent Changes the Follow-Up Equation

Qlar's hc-followup agent is a fully automated AI agent that operates via WhatsApp — Indonesia's dominant communication platform — to maintain continuous, personalized contact with diabetic patients between hospital visits. It requires zero daily administrative effort after initial configuration and operates 24 hours a day, 7 days a week.

For a diabetic patient enrolled in the program, here is what automated engagement looks like across a typical care cycle:

• Medication reminders: The agent sends personalized reminders aligned to each patient's specific prescription schedule — once daily for metformin users, twice daily for those on insulin combinations — with timing that matches the patient's reported routine.
• Routine check-up alerts: For BPJS patients managing Type 2 diabetes, the agent proactively messages patients 7 days and 2 days before their scheduled monthly or quarterly check-up, including details on what to bring (lab results, medication list) and how to reschedule if needed.
• Post-hospitalization follow-up: After any inpatient episode, the agent begins a structured 30-day recovery check-in sequence, asking about blood glucose readings, medication compliance, dietary adherence, and any symptoms of concern.
• Patient-reported outcome surveys (PROMs): Brief WhatsApp surveys (3–5 questions) collect self-reported wellbeing scores, enabling clinical teams to track patient-perceived health without requiring an office visit.
• Symptom escalation: When a patient reports symptoms that indicate potential complication — severe hypoglycemia, chest pain, vision changes, foot wounds — the agent immediately escalates to the clinical team for urgent follow-up, functioning as an always-on early warning system.

“Text messaging interventions have shown consistent effectiveness in improving medication adherence across chronic diseases, with SMS reminders nearly doubling the odds of patients achieving adherence targets — increasing rates from 50% to 67.8%.” — Systematic Review, PMC / JMCP, 2020^[6]

Before vs. After: The Measurable Impact of Automated Follow-Up

The WhatsApp Advantage in Indonesia's Healthcare Context

The channel choice matters enormously. Indonesia has one of the highest WhatsApp penetration rates in Asia — over 100 million active users, with WhatsApp being the default personal messaging platform for both urban and rural populations. Phone calls from unknown hospital numbers go unanswered. Email is rarely checked by the average patient. But a WhatsApp message from a familiar number — especially one that has previously confirmed an appointment — gets read.

This is why Qlar's hc-followup agent operates natively over WhatsApp. The agent messages patients using the same interface they use to communicate with family and colleagues. The familiarity reduces friction. The conversational format — as opposed to a formal SMS or email — feels personal even when automated. And critically, it allows two-way interaction: a patient can reply “I'm feeling dizzy today” and the agent will immediately assess severity, ask follow-up questions, and escalate if warranted.

For Puskesmas and RS type C and D facilities operating with limited administrative staff, the zero-overhead nature of the hc-followup agent is particularly valuable. Once configured, no staff member needs to manually initiate a single patient contact — the system handles every reminder, every survey, every escalation flag. Staff time is redirected to clinical care, not communications logistics.

From 19 Million Patients to an Actionable Program: Getting Started

The scale of Indonesia's diabetes burden is not a reason for paralysis — it is a reason for urgency. Every hospital that implements a structured AI follow-up program for its existing diabetes cohort captures a measurable share of the population that is currently falling through the cracks. The technology to do this exists today. It does not require a complex integration, a large IT budget, or months of implementation.

Qlar's hc-followup agent can be configured around a hospital's existing patient data and launched via WhatsApp Business within days. The agent is trained on the specific follow-up protocols of each facility — whether that is a Puskesmas managing a prolanis program or a private RS running a premium diabetes management clinic — and operates continuously from that point forward.

The business case is straightforward: a hospital with 500 active diabetes patients that improves routine check-up attendance by 60% adds approximately 300 additional outpatient visits per check-up cycle. At an average outpatient consultation and lab cost of Rp 200,000–500,000 per visit, that represents Rp 60–150 million in recovered revenue per cycle — before counting the downstream savings from prevented complications and emergency readmissions.

Conclusion: The Gap Is Where the Opportunity Lives

Indonesia's diabetes crisis will not be solved in the hospital ward. It will be solved — or worsened — in the weeks and months between clinic visits, when patients are on their own, managing a complex chronic condition with limited support. The hospitals that recognize this and build infrastructure for continuous patient engagement will see better clinical outcomes, stronger patient retention, and a more sustainable chronic disease program.

Qlar's hc-followup agent is that infrastructure — automated, personalized, operating on the platform patients already use, requiring zero ongoing administrative effort. For the 68% of diabetic patients who currently disappear after their first diagnosis, an AI that reaches out every week via WhatsApp is not a luxury. It is the difference between a patient who manages their condition and one who returns to the ICU.

The technology is ready. The need is documented. The question is whether Indonesia's hospitals will act before the next complication wave arrives — or after.

Sources

• ^[1] International Diabetes Federation (IDF). IDF Diabetes Atlas, 11th Edition. diabetesatlas.org/data-by-location/country/indonesia/
• ^[2] Lestari et al. “Medication Adherence in Patients with Diabetes Mellitus and Influencing Factors in Indonesia.” Diabetes & Endocrinology Journal, 2023. doi:10.14341/DM13068
• ^[3] Soewondo P et al. “Projection of diabetes morbidity and mortality till 2045 in Indonesia.” Scientific Reports, Nature, 2024. doi:10.1038/s41598-024-54563-2
• ^[4] Wulandari et al. “A National Survey of Adherence to Glucose-Lowering Medication Among Adults With Diabetes in Indonesia.” Tropical Medicine & International Health, Wiley, 2025. [journal]
• ^[5] Srinøy et al. “Rate and predictors for non-attendance of patients undergoing hospital outpatient treatment for chronic diseases.” BMC Health Services Research, 2019. PMC6570866
• ^[6] Marciano L et al. “Effectiveness of Mobile Applications on Medication Adherence in Adults with Chronic Diseases.” Journal of Managed Care & Specialty Pharmacy, 2020. PMC10391210